Form 8-K

8-K — TELA Bio, Inc.

Accession: 0001104659-26-093371

Filed: 2026-08-10

Period: 2026-08-10

CIK: 0001561921

SIC: 3841 (SURGICAL & MEDICAL INSTRUMENTS & APPARATUS)

Item: Results of Operations and Financial Condition

Item: Financial Statements and Exhibits

Documents

8-K — tm2622768d1_8k.htm (Primary)

EX-99.1 — EXHIBIT 99.1 (tm2622768d1_ex99-1.htm)

GRAPHIC (tm2622768d1_ex99-1img001.jpg)

XML — IDEA: XBRL DOCUMENT (R1.htm)

8-K — FORM 8-K

8-K (Primary)

Filename: tm2622768d1_8k.htm · Sequence: 1

false

0001561921

2026-08-10

iso4217:USD

xbrli:shares

iso4217:USD

xbrli:shares

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d)

of The Securities Exchange Act of 1934

Date of Report (Date of earliest event reported):

August 10, 2026

TELA

Bio, Inc.

(Exact name of registrant as specified in its

charter)

Delaware

001-39130

45-5320061

(State or other jurisdiction of

incorporation)

(Commission

File Number)

(I.R.S. Employer

Identification No.)

Great Valley Parkway, Suite 24

Malvern,

Pennsylvania

19355

(Address of principal executive offices)

(Zip Code)

Registrant’s telephone number, including

area code: (484) 320-2930

Not Applicable

(Former name or former address, if changed

since last report.)

Check the appropriate box below if the Form 8-K

filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

Written communications pursuant to Rule 425 under the Securities Act

(17 CFR 230.425)

Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange

Act (17 CFR 240.14d-2(b))

Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange

Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of

the Act:

Title of each class

Trading

Symbol(s)

Name of each exchange on which

registered

Common

Stock, par value $0.001 per share

TELA

Nasdaq

Global Market

Indicate by check mark whether the registrant is

an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2

of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company ¨

If an emerging growth company, indicate by check

mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting

standards provided pursuant to Section 13(a) of the Exchange Act. ¨

Item 2.02

Results of Operations and Financial Condition.

On August 10, 2026, TELA Bio, Inc. (the “Company”)

issued a press release announcing its financial results for the second quarter ended June 30, 2026. A copy of this press release is furnished

as Exhibit 99.1 hereto.

The information furnished pursuant to this Item 2.02, including Exhibit

99.1, shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange

Act”), or otherwise subject to the liabilities of that section, and shall not be deemed to be incorporated by reference

in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific reference in

such filing.

Item 9.01

Financial Statements and Exhibits.

(d) Exhibits

The following exhibits are being furnished herewith:

Exhibit No.

Document

99.1

Press Release of TELA Bio, Inc., dated August 10, 2026.

104

Cover Page Interactive Data File (embedded within the Inline XBRL document).

SIGNATURES

Pursuant to the requirements of the Securities

Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

TELA BIO, INC.

By:

/s/ Heather Getz

Name:

Heather Getz

Title:

Chief Executive Officer and Director

Date: August 10, 2026

EX-99.1 — EXHIBIT 99.1

EX-99.1

Filename: tm2622768d1_ex99-1.htm · Sequence: 2

Exhibit 99.1

TELA Bio Reports Second Quarter 2026 Financial

Results

MALVERN, PA, August 10,

2026 -- TELA Bio, Inc. (“TELA Bio”), a commercial-stage medical technology company focused on providing innovative soft-tissue

reconstruction solutions, today reported financial results for the second quarter ended June 30, 2026.

Recent Highlights

● Announced appointment of Heather Getz as Chief Executive Officer

and Director, effective August 4, 2026;

● Delivered international

revenue growth of 26% over the prior year period, with continued momentum in several European

markets;

● Achieved additional market share gain with OviTex unit volume

growth of 12% over the prior year period;

● Grew LiquiFix revenue by 39% over the prior-year period; and

● Delivered $19.3 million revenue in the second quarter of 2026,

representing a decline of 4% from the prior year period, primarily the result of a decline

in OviTex PRS unit volumes.

“I am honored to join TELA Bio at such an exciting time in the

Company's evolution. One reason I joined TELA is the superiority of our differentiated product portfolio. OviTex long-term data has continuously

shown recurrence rates in the low single-digits, whereas other hernia repair materials have recurrence rates consistently 10 times higher

than that.

“Unfortunately, the financial performance of the business does

not reflect the superiority of the portfolio. Our second quarter revenue was negatively impacted by a decline in OviTex PRS volumes and

continued price and mix headwinds in hernia procedures. In response, we have returned to a sales structure designed to reinforce cross-selling

among our field teams, and with a clear focus on returning to growth in the second half the year,” said Heather Getz, newly appointed

Chief Executive Officer of TELA Bio.

“We also continue to battle against the competitive dynamics

of bundling from our largest competitors and to combat this, we have upgraded talent within our Market Access and Contracting team. We

are encouraged by several indicators of progress across the business. Hernia unit volumes grew 12% year over year, demonstrating continued

procedural market share gains, while ASP and procedure mix begin to stabilize. International revenue also continued to grow, and our

field organization is progressing toward the productivity levels we expected as newer territory managers gain experience."

Ms. Getz continued, “Given the confluence of these dynamics,

we are withdrawing our full year 2026 revenue guidance as I fully assess the business and strategic direction. What is clear to me is

that as we move through the second half of the year, we must improve PRS performance, accelerate our market share gains in hernia, and

translate the increasing productivity of our commercial organization into sustainable top-line growth. At the same time, we will take

decisive action to extend our cash runway and better align our cost structure with our top line.

We are focused on disciplined execution and creating long-term value for all our stakeholders.”

Second Quarter 2026 Financial Results

Revenue was $19.3 million in the second quarter of 2026, a decrease

of 4% compared to $20.2 million in the second quarter of 2025. The decrease was primarily driven by a decline in OviTex PRS volumes and

price mix headwinds, partially offset by growing international sales.

Gross profit was $13.9 million, or 72% of revenue, in the second quarter

of 2026, compared to $14.1

million, or 70% of revenue, in the same period in 2025. The increase

in gross margin was primarily due to a tariff refund and a lower charge for excess and obsolete inventory as a percentage of revenue.

Operating expenses were $23.2 million in both the second quarter of

2026 and 2025. There was a de minimis increase due to higher meeting and training costs and increased professional fees partially offset

by lower compensation and benefits from lower headcount, lower commission expense, and lower study costs.

Loss from operations was $9.3 million in the second quarter of 2026,

compared to $9.1 million in the same period in 2025.

Net loss was $11.3 million in the second quarter of 2026, compared

to a net loss of $9.9 million in the same period in 2025.

Cash and cash equivalents on June 30, 2026 were $30.4 million.

2026 Financial Guidance

The Company has withdrawn full-year guidance and will provide an update

in the future.

Conference Call

TELA Bio will host a conference call at 4:30

p.m. Eastern Time on Monday, August 10, 2026 to discuss its second quarter financial results. Investors interested in listening to the

conference call should register online. Participants are required to register a day in advance or at minimum 15 minutes before the start

of the call. A replay of the webcast can be accessed via the Events & Presentations page of the investor section of TELA Bio's website.

About TELA Bio, Inc.

TELA Bio, Inc. (NASDAQ: TELA) is a commercial-stage medical technology

company focused on providing innovative technologies that optimize clinical outcomes by prioritizing the preservation and restoration

of the patient's own anatomy. The Company is committed to providing surgeons with advanced, economically effective soft-tissue reconstruction

solutions that leverage the patient's natural healing response while minimizing long-term exposure to permanent synthetic materials.

For more information, visit www.telabio.com.

Caution Regarding Forward-Looking Statements

This press release contains forward-looking statements within the

meaning of The Private Securities Litigation Reform Act of 1995. Words such as “may,” “might,” “will,”

“should,” “believe,” “expect,” “anticipate,” “estimate,” “continue,”

“predict,” “forecast,” “project,” “plan,” “intend” or similar expressions,

or statements regarding intent, belief, or current expectations are forward-looking statements and reflect the current beliefs of TELA

Bio's management. Such forward-looking statements include statements relating to our expected revenue and revenue growth for the full

year 2026 and reduction in operating expenses throughout the full year 2026 compared to prior periods and our expectations regarding

new product launch and expectations on market penetration and profitability. These statements are not guarantees of future performance

and are subject to certain risks, uncertainties and other factors that could cause actual results and events to differ materially and

adversely from those indicated by such forward-looking statements including, among others: the impact to our business from macroeconomic

conditions, including recessionary concerns, banking instability, increasing market interest rates, monetary policy changes, changes

in trade policies, including tariffs and trade protection measures, and inflationary pressures, potentially impacting our ability to

market our products, including the launch of new products; demand for our products related to changes in volumes or frequency of surgical

procedures, including due to outbreak of illness or disease, cybersecurity events impacting hospital operations, potential hospital closures,

labor and hospital staffing shortages, supply chain disruptions to critical surgical and hospital supplies, pricing pressures or any

other applicable adverse healthcare economic factors; our ability to achieve or sustain profitability; our ability to gain market acceptance

for our products and to accurately forecast and meet customer demand; our ability to compete successfully; that data from earlier studies

related to our products and interim data from ongoing studies may not be replicated in later studies or indicative of future data; that

data obtained from clinical studies using our product may not be indicative of outcomes in other surgical settings; our ability to enhance

our product offerings, including successful launch of new products; our ability to maintain expanded market access; product development

and manufacturing problems; capacity constraints or delays in production of our products; maintenance of coverage and adequate reimbursement

for procedures using our products; and product defects or failures. These risks and uncertainties are described more fully in the “Risk

Factors” section and elsewhere in our filings with the Securities and Exchange Commission and available at www.sec.gov, including

in our Annual Report on Form 10-K and Quarterly Reports on Form 10-Q. Any forward-looking statements that we make in this announcement

speak only as of the date of this press release, and TELA Bio assumes no obligation to update forward-looking statements whether as a

result of new information, future events or otherwise after the date of this press release, except as required under applicable law.

Investor Contact

Louisa Smith

ir@telabio.com

TELA Bio, Inc.

Consolidated Balance Sheets

(In thousands, except share and per share amounts)

(Unaudited)

June 30,

December 31,

2026

2025

Assets

Current assets:

Cash and cash equivalents

$ 30,424

$ 50,845

Accounts receivable, net of allowances of $522 and $287

9,637

10,347

Inventory

11,059

11,016

Prepaid expenses and other current assets

3,371

3,373

Total current assets

54,491

75,581

Property and equipment, net

2,048

2,226

Intangible assets, net

1,169

1,359

Right-of-use assets

1,379

1,502

Other long-term assets

451

500

Restricted cash

200

250

Total assets

$ 59,738

$ 81,418

Liabilities and stockholders’ (deficit) equity

Current liabilities:

Accounts payable

$ 2,883

$ 2,309

Accrued expenses and other current liabilities

15,335

15,666

Total current liabilities

18,218

17,975

Long-term debt

56,081

55,653

Other long-term liabilities

1,305

1,477

Total liabilities

75,604

75,105

Stockholders’ (deficit) equity:

Preferred stock; $0.001 par value: 10,000,000 shares authorized; no shares issued and outstanding

—

Common stock; $0.001 par value: 200,000,000 shares authorized; 44,833,942 and 44,538,264 shares issued and outstanding at June 30, 2026 and December 31, 2025, respectively

Additional paid-in capital

405,101

403,739

Accumulated other comprehensive income

Accumulated deficit

(421,096 )

(397,561 )

Total stockholders’ (deficit) equity

(15,866 )

6,313

Total liabilities and stockholders’ (deficit) equity

$ 59,738

$ 81,418

TELA Bio, Inc.

Consolidated Statements of Operations and Comprehensive

Loss

(In thousands, except share and per share amounts)

(Unaudited)

Three months ended June 30,

Six months ended June 30,

2026

2025

2026

2025

Revenue

$ 19,291

$ 20,197

$ 38,350

$ 38,717

Cost of revenue (excluding amortization of intangible assets)

5,253

5,997

11,697

11,910

Amortization of intangible assets

190

Gross profit

13,943

14,105

26,463

26,617

Operating expenses:

Sales and marketing

16,442

16,857

32,979

33,465

General and administrative

4,061

4,126

8,227

7,962

Research and development

2,723

2,203

5,066

4,743

Total operating expenses

23,226

23,186

46,272

46,170

Loss from operations

(9,283 )

(9,081 )

(19,809 )

(19,553 )

Other (expense) income:

Interest expense

(2,076 )

(1,188 )

(4,129 )

(2,407 )

Other income

157

379

523

858

Total other expense, net

(1,919 )

(809 )

(3,606 )

(1,549 )

Loss before income tax expense

(11,202 )

(9,890 )

(23,415 )

(21,102 )

Income tax expense

(60 )

(33 )

(120 )

(85 )

Net loss

$ (11,262 )

$ (9,923 )

$ (23,535 )

$ (21,187 )

Net loss per common share, basic and diluted

$ (0.20 )

$ (0.22 )

$ (0.41 )

$ (0.47 )

Weighted average common shares outstanding, basic and diluted

57,414,360

45,365,325

57,335,875

45,316,444

Comprehensive loss:

Net loss

$ (11,262 )

$ (9,923 )

$ (23,535 )

$ (21,187 )

Foreign currency translation adjustment

(1 )

(7 )

Comprehensive loss

$ (11,263 )

$ (9,921 )

$ (23,542 )

$ (21,184 )

GRAPHIC

Filename: tm2622768d1_ex99-1img001.jpg · Sequence: 6

Binary file (5413 bytes)

Download tm2622768d1_ex99-1img001.jpg

XML — IDEA: XBRL DOCUMENT

XML

Filename: R1.htm · Sequence: 8

v3.26.1

Cover

Aug. 10, 2026

Cover [Abstract]

Document Type

8-K

Amendment Flag

false

Document Period End Date

Aug. 10, 2026

Entity File Number

001-39130

Entity Registrant Name

TELA

Bio, Inc.

Entity Central Index Key

0001561921

Entity Tax Identification Number

45-5320061

Entity Incorporation, State or Country Code

Entity Address, Address Line One

Great Valley Parkway

Entity Address, Address Line Two

Suite 24

Entity Address, City or Town

Malvern

Entity Address, State or Province

Entity Address, Postal Zip Code

19355

City Area Code

484

Local Phone Number

320-2930

Written Communications

false

Soliciting Material

false

Pre-commencement Tender Offer

false

Pre-commencement Issuer Tender Offer

false

Title of 12(b) Security

Common

Stock, par value $0.001 per share

Trading Symbol

TELA

Security Exchange Name

NASDAQ

Entity Emerging Growth Company

false

- Definition

Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.

+ References

No definition available.

+ Details

Name:

dei_AmendmentFlag

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration

- Definition

Area code of city

+ References

No definition available.

+ Details

Name:

dei_CityAreaCode

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

Cover page.

+ References

No definition available.

+ Details

Name:

dei_CoverAbstract

Namespace Prefix:

dei_

Data Type:

xbrli:stringItemType

Balance Type:

Period Type:

duration

- Definition

For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.

+ References

No definition available.

+ Details

Name:

dei_DocumentPeriodEndDate

Namespace Prefix:

dei_

Data Type:

xbrli:dateItemType

Balance Type:

Period Type:

duration

- Definition

The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.

+ References

No definition available.

+ Details

Name:

dei_DocumentType

Namespace Prefix:

dei_

Data Type:

dei:submissionTypeItemType

Balance Type:

Period Type:

duration

- Definition

Address Line 1 such as Attn, Building Name, Street Name

+ References

No definition available.

+ Details

Name:

dei_EntityAddressAddressLine1

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

Address Line 2 such as Street or Suite number

+ References

No definition available.

+ Details

Name:

dei_EntityAddressAddressLine2

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

Name of the City or Town

+ References

No definition available.

+ Details

Name:

dei_EntityAddressCityOrTown

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

Code for the postal or zip code

+ References

No definition available.

+ Details

Name:

dei_EntityAddressPostalZipCode

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

Name of the state or province.

+ References

No definition available.

+ Details

Name:

dei_EntityAddressStateOrProvince

Namespace Prefix:

dei_

Data Type:

dei:stateOrProvinceItemType

Balance Type:

Period Type:

duration

- Definition

A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection b-2

+ Details

Name:

dei_EntityCentralIndexKey

Namespace Prefix:

dei_

Data Type:

dei:centralIndexKeyItemType

Balance Type:

Period Type:

duration

- Definition

Indicate if registrant meets the emerging growth company criteria.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection b-2

+ Details

Name:

dei_EntityEmergingGrowthCompany

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration

- Definition

Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.

+ References

No definition available.

+ Details

Name:

dei_EntityFileNumber

Namespace Prefix:

dei_

Data Type:

dei:fileNumberItemType

Balance Type:

Period Type:

duration

- Definition

Two-character EDGAR code representing the state or country of incorporation.

+ References

No definition available.

+ Details

Name:

dei_EntityIncorporationStateCountryCode

Namespace Prefix:

dei_

Data Type:

dei:edgarStateCountryItemType

Balance Type:

Period Type:

duration

- Definition

The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection b-2

+ Details

Name:

dei_EntityRegistrantName

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection b-2

+ Details

Name:

dei_EntityTaxIdentificationNumber

Namespace Prefix:

dei_

Data Type:

dei:employerIdItemType

Balance Type:

Period Type:

duration

- Definition

Local phone number for entity.

+ References

No definition available.

+ Details

Name:

dei_LocalPhoneNumber

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 13e

-Subsection 4c

+ Details

Name:

dei_PreCommencementIssuerTenderOffer

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration

- Definition

Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 14d

-Subsection 2b

+ Details

Name:

dei_PreCommencementTenderOffer

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration

- Definition

Title of a 12(b) registered security.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection b

+ Details

Name:

dei_Security12bTitle

Namespace Prefix:

dei_

Data Type:

dei:securityTitleItemType

Balance Type:

Period Type:

duration

- Definition

Name of the Exchange on which a security is registered.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection d1-1

+ Details

Name:

dei_SecurityExchangeName

Namespace Prefix:

dei_

Data Type:

dei:edgarExchangeCodeItemType

Balance Type:

Period Type:

duration

- Definition

Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 14a

-Subsection 12

+ Details

Name:

dei_SolicitingMaterial

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration

- Definition

Trading symbol of an instrument as listed on an exchange.

+ References

No definition available.

+ Details

Name:

dei_TradingSymbol

Namespace Prefix:

dei_

Data Type:

dei:tradingSymbolItemType

Balance Type:

Period Type:

duration

- Definition

Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Securities Act

-Number 230

-Section 425

+ Details

Name:

dei_WrittenCommunications

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration